Development of alopecia areata universalis in a patient receiving adalimumab.
Garcia Bartels
Natalie
N
Lee
Hae-Huyk
HH
Worm
Margitta
M
Burmester
Gerd-Rüdiger
GR
Sterry
Wolfram
W
Blume-Peytavi
Ulrike
U
D000068879:Adalimumab; D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab